OncoTherapy Science Stock

OncoTherapy Science EBIT

The EBIT of OncoTherapy Science (4564.T) as of Aug 17, 2026 is -797.94 M JPY. In the previous year, EBIT was -1.12 B JPY — a change of -28.81% (higher).

EBIT

-797.94 MJPY

YoY

-28.81%

Last updated:

In 2026, OncoTherapy Science's EBIT was -797.94 M JPY, a -28.81% increase from the -1.12 B JPY EBIT recorded in the previous year.

The OncoTherapy Science EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B JPY)
Date
EBIT (B JPY)
Jan 1, 2018
-2.99 base
Jan 1, 2019
-2.95 base
Jan 1, 2020
-2.19 base
Jan 1, 2021
-1.64 base
Jan 1, 2022
-2.05 base
Jan 1, 2023
-1.11 base
Jan 1, 2024
-1.12 base
Jan 1, 2025
-0.80 base
YEAREBIT (B JPY)
2025 -0.80
2024 -1.12
2023 -1.11
2022 -2.05
2021 -1.64
2020 -2.19
2019 -2.95
2018 -2.99
2017 -3.00
2016 -2.98
2015 -1.96
2014 -3.79
2013 -1.11
2012 1.18
2011 0.22
2010 0.33
2009 0.04
2008 -0.38
2007 -1.35
2006 -0.83
Access this data via the Eulerpool API

OncoTherapy Science Revenue

OncoTherapy Science Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
211.25 M JPY
-2.99 B JPY
-2.85 B JPY
Jan 1, 2019
280.59 M JPY
-2.95 B JPY
-2.93 B JPY
Jan 1, 2020
316.22 M JPY
-2.19 B JPY
-2.24 B JPY
Jan 1, 2021
332.48 M JPY
-1.64 B JPY
-1.56 B JPY
Jan 1, 2022
1.15 B JPY
-2.05 B JPY
-2.57 B JPY
Jan 1, 2023
1.13 B JPY
-1.11 B JPY
-1.12 B JPY
Jan 1, 2024
610.12 M JPY
-1.12 B JPY
-1.29 B JPY
Jan 1, 2025
750.05 M JPY
-797.94 M JPY
-815.29 M JPY

OncoTherapy Science Margins

OncoTherapy Science stock margins

The OncoTherapy Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OncoTherapy Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OncoTherapy Science.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
-1.70 %
-1,414.71 %
-1,349.62 %
Jan 1, 2019
-1.70 %
-1,052.72 %
-1,046.01 %
Jan 1, 2020
-15.85 %
-692.46 %
-707.92 %
Jan 1, 2021
5.88 %
-492.65 %
-469.70 %
Jan 1, 2022
9.87 %
-177.92 %
-222.90 %
Jan 1, 2023
3.67 %
-97.49 %
-98.57 %
Jan 1, 2024
-29.13 %
-183.70 %
-211.13 %
Jan 1, 2025
-1.70 %
-106.38 %
-108.70 %

OncoTherapy Science Stock analysis

What does OncoTherapy Science do? OncoTherapy Science Inc is a rising company that focuses on the research and development of novel cancer therapies. The company takes pride in being able to combine the latest scientific findings with cutting-edge technologies to develop highly effective drugs and therapies that can improve the lives of cancer patients. The company is based in Japan and was founded in 2001. Since its inception, it has become one of the leading companies in cancer research and its products are available worldwide. OncoTherapy Science Inc's business model is based on the development and commercialization of new innovative cancer therapies. The company utilizes the latest technologies and research findings to achieve groundbreaking advancements in cancer treatment. These innovative therapies have the potential to improve the survival and quality of life of cancer patients. OncoTherapy Science Inc divides its activities into various areas. This includes the research and development of drugs, the clinical testing of new therapies, and the production and commercialization of cancer therapies. The research and development of new drugs form the core of OncoTherapy Science Inc's activities. The company continuously invests in researching new treatment approaches to improve the effectiveness and safety of cancer therapies. Advanced technologies such as genome sequencing and molecular diagnostics are utilized to develop personalized therapies tailored to specific types of cancer and patients. OncoTherapy Science Inc also conducts extensive clinical trials to evaluate the effectiveness and safety of its therapies. The success rate of clinical studies is very high, and many of the therapies have already received approval from regulatory authorities. Another important area of OncoTherapy Science Inc is the production and commercialization of cancer therapies. The company works closely with its distribution partners to ensure that its products are available in many countries and regions. OncoTherapy Science Inc's therapies are recommended by many oncologists and used in leading clinical institutions worldwide. Products of OncoTherapy Science Inc include a range of innovative cancer therapies. These include antibody-based drugs, immunotherapies, RNA-based therapies, and chemotherapy. These therapies have the potential to improve the effectiveness of cancer treatment and enhance the quality of life of cancer patients. An example of an innovative therapy by OncoTherapy Science Inc is OTS964, a new chemotherapeutic agent for the treatment of pancreatic cancer and other cancers. OTS964 inhibits the enzyme TOPK, which is overexpressed in many types of cancer, leading to the death of cancer cells. This therapy has shown promising results in animal models and is currently being tested in clinical trials. OncoTherapy Science Inc aims to contribute to improving the quality of life of cancer patients. The company relies on a combination of innovative research, state-of-the-art technology, and close collaboration with other industry stakeholders to achieve a leading position in cancer research. With its strong market position and commitment to cancer research, OncoTherapy Science Inc is a company that will achieve much in the future. OncoTherapy Science is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing OncoTherapy Science's EBIT

OncoTherapy Science's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of OncoTherapy Science's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

OncoTherapy Science's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in OncoTherapy Science’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about OncoTherapy Science stock

EBIT of OncoTherapy Science is -797.94 M JPY in 2026.

EBIT of OncoTherapy Science changed from -1.12 B JPY to -797.94 M JPY, representing a -28.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT OncoTherapy Science since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's OncoTherapy Science historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — OncoTherapy Science

All Key Metrics — OncoTherapy Science